Optimizing Care in Perioperative Immunotherapy for Gastric/Gastroesophageal Junction Adenocarcinoma: Case-Based Insights and Multidisciplinary Collaboration

Please visit answersincme.com/860/102331945-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Elizabeth Smyth, MD, FRCP and Daniela Molena, MD. In this activity, experts in gastric/gastroesophageal junction adenocarcinoma discuss the latest evidence and practical strategies for optimizing the treatment of resectable gastric (G)/gastroesophageal junction (GEJ) adenocarcinoma with perioperative immunotherapy. Upon completion of this activity, participants should be better able to: Evaluate the evidence supporting the integration of perioperative immunotherapy (IO) in the treatment of resectable gastric (G)/gastroesophageal junction (GEJ) adenocarcinoma; Analyze the role of biomarkers in decision-making for perioperative IO in resectable G/GEJ adenocarcinoma; and Outline multidisciplinary strategies for optimizing the care of patients receiving perioperative IO for resectable G/GEJ adenocarcinoma.